What was the purpose of this study?
This study looked at the results and safety of ORENCIA IV compared with placebo IV after 6 months.
Characteristics that children needed to have in order to be included in this study:
- 6 to 17 years old
- Living with moderately to severely active pJIA
- Not helped by one or more DMARDs
What was compared in this study?
Initially, there were 190 children in this study. After 4 months, 68 of those children either did not complete the study or did not respond to the treatment according to the American College of Rheumatology (ACR) criteria and were excluded. The remaining children who had reduced signs and symptoms were then split into 2 groups to help compare their responses to treatment. One group of 60 children received ORENCIA, and the other group of 62 children received placebo.
In children and adolescents, other side effects may include:
- Diarrhea
- Cough
- Fever
- Abdominal pain